



thebreastcentre.com.au

INVASIVE BREAST CANCER DIAGNOSIS
 BILATERAL MAMMOGRAM
 BREAST ULTRASOUND
 CORE BIOPSY BREAST
 ?CORE BIOPSY/FNA AXILLARY NODE
 CLINICAL BREAST EXAMINATION
 ?BREAST MRI
 ?GENETIC TESTING

BREAST CANCER TREATMENT ALGORITHM

Jane O'Brien MBBS FRACS
 Specialist Oncoplastic Breast Cancer Surgeon

**"NON OPERABLE" INVASIVE BREAST CANCER DIAGNOSIS(T4)
 LOCALLY ADVANCED BREAST CANCER(LABC) WITH SKIN INVOLVEMENT
 INFLAMMATORY BREAST CANCER(IBC)**

SURGERY

BCT-BREAST CONSERVING THERAPY
 LUMPECTOMY/WIDE LOCAL EXCISION
 SLNB-SENTINEL NODE BIOPSY
 ALND-AXILLARY NODE DISSECTION/CLEARANCE
 XRT-RADIATION
 PMRT-POST MASTECTOMY RADIATION
 NSM-NIPPLE-SPARING MASTECTOMY
 SSM-SKIN-SPARING MASTECTOMY
 HR+HORMONE RECEPTOR+ VE

ER/PR+HER2- LUMINAL A

HER2+ OR TNBC SMALL TUMOUR (T1) NODE NEGATIVE (N0)

HER2+ OR TNBC ?LUMINAL B LARGE TUMOUR (T2/3) NODE POSITIVE (N1)

TNBC: ANTHRACYCLINE TAXANE SEQUENCE +/- PLATINUM

HER2+ ANTHRACYCLINE TAXANE SEQUENCE PLUS DUAL HER2 BLOCKADE WITH TRASTUZUMAB AND PERTUZUMAB (HERCEPTIN AND PERJETA)

SUITABLE DOWNSTAGING BREAST OR AXILLA

SUITABLE SLNB+/- EXCISION CLIPPED NODE

INITIAL SURGERY

SUITABLE BCT

PATIENT CHOICE

MASTECTOMY

DESIRES IMMEDIATE RECONSTRUCTION

NSM

SSM

MASTECTOMY

SUITABLE SLNB

SUITABLE SLNB

SUITABLE BCT

SUITABLE BCT

MASTECTOMY/SLNB

WLE/SLNB

WLE/ALND

MASTECTOMY/ALND

WLE/SLNB+/- ONCOPLASTIC

WLE/ALND+/- ONCOPLASTIC

POSITIVE SLN

SLN-

0,1 OR 2+ SLN

2+ SLN

XRT ONLY

ALND

NIPPLE DELAY

NIPPLE DELAY/SLNB

SLNB

NSM/RECON/ALND

NSM/RECON

SSM/RECON

SSM/RECON/ALND

MASTECTOMY/SLNB

MASTECTOMY/ALND

? PMRT

PMRT

BREAST XRT

BREAST XRT

PMRT

ADJUVANT CHEMO

XRT

ENDOCRINE THERAPY

CHEMOTHERAPY IF REQUIRED:
 CONSIDER GENOMIC TEST IF HR+
 ANTHRACYCLINE/TAXANE SEQUENCE OR DOCETAXOL/CYCLOPHOSPHAMIDE +/- HER2 BLOCKADE (HERCEPTIN) OR PACLITAXEL/ERCEPTIN

IF CPR:
 IF HER2+ COMPLETE ANTI HER2 THERAPY FOR 1 YR

IF NON CPR:
 TNBC-ADJUVANT CAPECITABINE
 HER2+ TDM1(KADCYLA)

RADIO THERAPY TO CONSERVED BREAST

POSTMASTECTOMY RADIO THERAPY (PMRT)

ANTIOESTROGEN THERAPY IF HR+:
 ADJUVANT ENDOCRINE THERAPY; MINIMUM 5 YRS; IF HIGH RISK EXTENDED FOR UP TO 7-10 YRS
 PREMENOPAUSAL: TAMOXIFEN; IF HIGH RISK GHRN ANALOGUE(ZOLADEX) AND TAMOXIFEN OR AROMATASE INHIBITOR
 POSTMENOPAUSAL: AROMATASE INHIBITOR OR TAMOXIFEN UPFRONT OR IN SEQUENCE WITH EACH OTHER

NEO ADJUVANT THERAPY

SURGERY

XRT

? ADJUVANT THERAPY

ENDOCRINE THERAPY